Last reviewed · How we verify
Low dose oral anticoagulant
Low-dose oral anticoagulants inhibit blood coagulation factors to reduce thrombus formation while minimizing bleeding risk through reduced dosing.
Low-dose oral anticoagulants inhibit blood coagulation factors to reduce thrombus formation while minimizing bleeding risk through reduced dosing. Used for Thromboprophylaxis or stroke prevention (specific indication unclear without additional product details).
At a glance
| Generic name | Low dose oral anticoagulant |
|---|---|
| Also known as | Edoxaban of 30mg |
| Sponsor | Korea University Guro Hospital |
| Drug class | Oral anticoagulant |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
These agents work by inhibiting key factors in the coagulation cascade (such as Factor Xa or thrombin) at sub-therapeutic doses, providing anticoagulant activity sufficient to prevent pathological clotting while maintaining a favorable safety profile compared to standard-dose anticoagulation. The reduced dose strategy aims to balance efficacy in thromboprophylaxis or treatment with lower rates of major bleeding complications.
Approved indications
- Thromboprophylaxis or anticoagulation (specific indication not detailed)
Common side effects
- Bleeding
- Gastrointestinal disturbance
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Design and Rationale of the COLT Study (PHASE3)
- Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress (PHASE4)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing (PHASE3)
- SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose oral anticoagulant CI brief — competitive landscape report
- Low dose oral anticoagulant updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI